Michael-Rock Goldsmith

Co-founder & Chief Innovation Scientist @Congruence Therapeutics

Durham, NC, US
MOBILE NUMBERS
+91 *********19

Signup · Get unlimited contacts

WORK HISTORY

May 2021 — Present

Co-founder & Chief Innovation Scientist @Congruence Therapeutics

View department →

Raleigh-Durham-Chapel Hill, NC, US

Congruence Therapeutics is a biotechnology company using a unique computational platform to develop pharmacological stabilizers for rare diseases.

EDUCATION

2001 — 2005

Duke University

Ph.D., Computational Chemistry

1995 — 1998

Concordia University

B.Sc. Honors - CO-OP, Chemistry

1993 — 1995

Marianopolis College

DEC, Health Sciences

1985 — 1993

Lower Canada College

Secondary School Diploma

SKILLS

Computational ToxicologyMolecular ModelingEnvironmental ToxicologyQsarScientific ComputingDockingHtsProduct EngineeringToxicologyHigh Throughput ScreeningBiochemistryGenomicsIn VitroBioinformaticsAdmeDrug DiscoverySciencePredictive ModelingComputational BiologyComputational ChemistryChemistryProtein ChemistryIn VivoCharacterizationMedicinal ChemistryLaboratoryLife SciencesBiotechnology

ABOUT MICHAEL-ROCK GOLDSMITH

Specialties: docking, QSAR, conformational analysis, vHTS, computational/predictive toxicology, product engineering, formulation and kinetic optimization/design, scientific computing, ecological epidemiology, passive interrogation, computational discovery chemistry for biologically active small molecules

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.